Company Overview

This new article from Coriolis Pharma highlights how early developability assessments can prevent late-stage failures. By integrating lab-based and in-silico analyses, Coriolis identifies risks early, optimizes formulations, and supports faster, more cost-effective drug development from discovery to market.

This webinar presents a comprehensive overview of a lyophilization model including a robustness analysis, highlighting the significance of predictive models and robustness assessment methodologies in optimizing process parameters and ensuring product quality.

This new article from Coriolis Pharma explores how lyophilization supports the stability and scalability of biologics. By combining quality-by-design, predictive modeling, and advanced freeze-drying technologies, Coriolis ensures robust, manufacturable formulations ready for global deployment.

The on-demand webinar includes case studies demonstrating in silico modeling’s role in developability assessment and early formulation development, highlighting how these approaches minimise risks, shorten development times, and enhance decision-making. 

This new article from Coriolis Pharma presents AI-powered flow imaging microscopy as a breakthrough in particle analysis. Through its partnership with ParticleSentryAI, Coriolis enables deeper particle insights, supporting better formulation decisions, improved product quality, and faster development of safe biopharmaceuticals.

This new article from Coriolis Pharma underscores the critical role of GMP-compliant analytical testing in ensuring drug quality and stability. It highlights the need for specialized methods to manage complexity, support regulatory compliance, and safeguard product integrity throughout development.

Coriolis Pharma’s team of experts specializes in lyophilization, bringing extensive experience in developing, optimizing, scaling up, and transferring lyophilization cycles for biopharmaceutical drug products. 

This new article from Coriolis Pharma emphasizes the importance of robust formulations for biologic drug success. It showcases Coriolis’ integrated, science-driven approach using in-silico tools and high-throughput methods to create stable, future-ready formulations from early development onward.

Our developability assessment service combines laboratory-based and in silico developability assessments to provide early insights into molecule characteristics and potential liabilities, optimize formulations, and mitigate risks. 

This new article from Coriolis Pharma highlights the growing need for high-concentration biologic formulations suited for self-administration. It outlines Coriolis’ expertise in overcoming formulation and packaging challenges to deliver stable, user-friendly therapies ready for clinical and commercial success.

In this webinar our experts talk about tools and methods for particle identification and characterization in biologics and gene and cell therapy drug products.